Dr Katherine Wu joins Ethics Talk to discuss her article, coauthored with Dr Erik Messamore: “Reimagining Roles of Dietary Supplements in Psychiatric Care.”
Kristen N. Pallok and David A. Ansell’s “Should Clinicians Be Activists?” highlights how physician activists risk retaliation from “economically and socially” privileged physician leaders and organizational leadership who “have been trained to comply” with structural inequity.
AMA J Ethics. 2022;24(7):E694-696. doi:
10.1001/amajethics.2022.694.
Dr Pilar Ortega joins Ethics Talk to discuss her article, coauthored with Drs Glenn Martínez, Marco A. Alemán, Alejandra Zapién-Hidalgo, and Tiffany M. Shin: “Recognizing and Dismantling Raciolinguistic Hierarchies in Latinx Health.”
Targeted dosing to treat pediatric inflammatory bowel disease is challenging because dosing guidelines are based on data gathered from adult subjects of clinical trials. Patients’ families and health care organizations also incur high costs and must try to balance potential benefits against risks of ongoing monitoring.
AMA J Ethics. 2018;20(9):E841-848. doi:
10.1001/amajethics.2018.841.
Given full information about the risks of long-term opioid therapy, patients often see the value of exploring other options rather than thinking their physicians are reluctant to prescribe narcotics for fear of litigation or regulatory action.
AMA J Ethics. 2015;17(3):202-208. doi:
10.1001/journalofethics.2015.17.3.ecas1-1503.
The drug Neurontin is used as an example of why it is permissible for physicians to engage in off-label prescribing, but off-label marketing by pharmaceutical companies is prohibited by the FDA.